Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis
about
Evaluation of a multiple sclerosis cluster among nurses in an inpatient oncology wardRole of immunosuppressive therapy for the treatment of multiple sclerosisSystolic blood pressure variability and lower extremity amputation in a non-elderly population with diabetes.Disease-modifying agents in multiple sclerosis.Promising treatments of tomorrow for multiple sclerosis.High-dose cyclophosphamide for severe aplastic anemia: long-term follow-upHematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.Aggressive multiple sclerosis: proposed definition and treatment algorithm.Lights and shadows of cyclophosphamide in the treatment of multiple sclerosisHigh-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseasesHigh-dose cyclophosphamide without stem cell rescue for the treatment of refractory Behcet's diseaseOptimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America.Repeated treatment with high dose cyclophosphamide for severe autoimmune diseasesTreatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosisNon-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies.Pathogenic mechanisms and experimental models of multiple sclerosis.Hematopoietic SCT for the treatment of multiple sclerosis.High-dose chemotherapy and multiple sclerosis.Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.Management of children with multiple sclerosis.Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents.Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion.Therapeutic management of severe relapses in multiple sclerosis.Clinical impact of HLA class I expression in rectal cancer.High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies.Characterising aggressive multiple sclerosis.Medication Treatment in Multiple Sclerosis
P2860
Q23912471-90C9C759-1898-4DE6-826E-E9012AAEC73DQ26827467-E77AFA87-0D4D-483C-ACC7-48CFC7FB8BB8Q30277672-C3ACF92A-EAB7-4CBB-A1E3-2B37F2A0B9F2Q33670940-B990BBA3-16E0-471C-97AE-42E16BEE81FCQ33670947-7BC4EEAF-340F-4A7C-B0F1-06CE8052E6EBQ33747331-E860BDB1-1084-4E95-B061-A869A4D2AADBQ33965239-6E82EF05-0B72-4297-904B-11EF43B18315Q34409273-66B6E01C-D8F9-4147-BD79-012E4BF2936DQ34478828-BCA57879-A5D3-4D04-B2AA-C87BD31835BAQ34922742-56995343-5830-4730-8A21-8C5BBD9F1F7FQ34986999-5B3BC878-6B12-4B6C-A0D1-BB48A93856AAQ35322297-55294D32-0540-4EB0-BEE6-EA55006F7604Q35588410-7A22301A-817C-47AE-A1A4-69D1B3E50765Q36562866-6468E36C-8CF4-4525-BC04-BFF1F233E159Q36730633-BDA08FCE-8B9B-40E4-BE87-DDEEEED6CAD1Q37052797-58F27342-28AD-400B-ACE7-1DAAC66C0187Q37124529-77588160-028C-4D54-9BC5-5E4AF269C1FBQ37562166-43A839A6-3D7D-4048-839F-05FD6044AC95Q37728003-C470EEAD-D585-4E33-B10D-2981DF9E5393Q37778984-9115C8C7-70E5-4B4F-A0F5-5DF08E6596A8Q37822255-2A73CAD9-E31F-4575-AC8D-79E586072D48Q37851885-DFEEB01D-2AE5-4EAF-A3E9-55AC69A8E249Q38002113-64C76B19-6997-40E3-9317-94FCDBD74753Q38051577-AFD9FD69-3D31-4750-B45A-9A7DDE9CF705Q38946338-83AAFAAA-9A26-47D1-BF1B-0B8601F2F402Q39026942-4DE89B9C-9104-4B45-A97C-2B7FF26F9A4DQ40173498-B84426C7-087A-4B8A-8D67-6B48A5DFD367Q41814408-7F9576C0-4ADD-49DC-9F4B-AC7D0FE4B710Q45145307-E5AAECF4-8313-46E3-944A-33727C7529F2Q57083576-2463C5A6-2DF4-4EA8-B71E-EC486D9C1A9F
P2860
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Reduction of disease activity ...... aggressive multiple sclerosis
@ast
Reduction of disease activity ...... aggressive multiple sclerosis
@en
Reduction of disease activity ...... aggressive multiple sclerosis
@nl
type
label
Reduction of disease activity ...... aggressive multiple sclerosis
@ast
Reduction of disease activity ...... aggressive multiple sclerosis
@en
Reduction of disease activity ...... aggressive multiple sclerosis
@nl
prefLabel
Reduction of disease activity ...... aggressive multiple sclerosis
@ast
Reduction of disease activity ...... aggressive multiple sclerosis
@en
Reduction of disease activity ...... aggressive multiple sclerosis
@nl
P2093
P2860
P1433
P1476
Reduction of disease activity ...... aggressive multiple sclerosis
@en
P2093
Adam I Kaplin
Avindra Nath
Benjamin M Greenberg
Carlos A Pardo
Carrilin Trecker
Chitra Krishnan
Daniel B Drachman
David M Yousem
Douglas A Kerr
Dzung L Pham
P2860
P304
P356
10.1001/ARCHNEUROL.65.8.NOC80042
P407
P577
2008-08-01T00:00:00Z